TGFB1 and cystic fibrosis: Targeting M2 macrophages in the CF microenvironment to drive their polarization into M1 macrophages and reduce the expression of profibrotic factors such as TGFβ while activating the expression of inflammatory factors may be an ideal treatment strategy for CF.